Pharmaceuticals & Therapeutics

A strategic partnership with 5 Horizons Ventures accelerates Marvel Biosciences' novel drug, MB-204, into human trials for autism, Rett syndrome, and more.

Early Phase 3 results show gotistobart dramatically extends survival for lung cancer patients with limited options, heralding a potential new standard of care.

A new bispecific antibody aims to treat the 50% of AxSpA patients who find no relief, as Fortitude Biomedicines enters a competitive autoimmune market.

A new partnership brings a groundbreaking protocol for corneal blindness to Chicago, expanding a national network dedicated to restoring vision for thousands.

As employers face staggering GLP-1 expenses, a new program aims to deliver measurable outcomes by integrating clinical support directly into pharmacy benefits.

Eosera just unveiled its largest product launch ever, aiming to become the authority in a growing OTC market with new solutions for pain, itch, and wellness.

A new poll shows two-thirds of workers are more likely to use GLP-1s with employer coverage, highlighting the role of cost, support, and stigma.

Life Sciences Ontario's new board appointments signal a strategic shift, bringing in leaders from medtech, agri-tech, pharma, and nuclear isotopes.

Royal Biologics' new Fibrinet system uses a patient's own blood to create a living bandage, a major step forward for treating diabetic and venous ulcers.

Backed by a $41.3M ARPA-H award, SonoNeu is pioneering sonogenetics, a non-invasive therapy using ultrasound to control cells and treat nerve pain.

The firm adds veteran TD Cowen analyst Boris Peaker to deepen its research in oncology and genetic medicines, signaling a major bet on specialized insight.

With diagnostic sales fueling a diverse therapeutic arsenal, Telix reaffirms blockbuster guidance and advances pivotal trials for prostate, brain, and kidney cancers.

Upsher-Smith launches its first prescription ear drop, a generic of Ciprodex®, entering a $118M market and promising a more affordable option for patients.

Apnimed has secured up to $150M to launch AD109, a potential first-ever pill for sleep apnea, promising relief for millions tired of CPAP machines.

New preclinical data for ATNM-400 and Actimab-A shows promise for treating resistant solid tumors and AML, highlighting a new frontier in cancer therapy.

A major lab expansion in Massachusetts aims to slash preclinical timelines for the most promising new cancer treatments, including advanced radiotherapies.

A new Concord research center combines patient care and clinical trials, promising to speed up breakthroughs for complex heart, kidney, and metabolic diseases.

With promising clinical data, Clarametyx promotes key executives to accelerate its novel attack on chronic respiratory disease biofilms. Jennifer Anderson reports.

Preclinical data suggests an investigational drug can shift burn wounds from a state of chronic inflammation toward active regeneration and repair.

AvenCell has dosed the first patient with AVC-203, a novel allogeneic CAR-T therapy, aiming to make advanced cancer treatment more accessible and effective.